PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

Key Points

• PVR (CD155) epigenetic status directly influences immunotherapy response.
• The study highlights a potential average survival difference of 12 months based on epigenetic modifications.
• Analysis reveals varying PVR (CD155) expression levels in multiple myeloma patients undergoing treatment.
• Understanding PVR (CD155) epigenetics may lead to improved immunotherapy strategies and patient outcomes.